Therefore, JAK1/JAK2 inhibition is shown to be a potential tool for improving health outcomes in patients inhibiting hyperglycemia-induced damage to kidney cells, improving renal function, reducing renal inflammation and fibrotic lesions and slowing the progression of DKD (Chen et al., 2021). This evidence concerns the gene JAK2 and diabetic kidney disease.